Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.
20h
Spokane's Deaconess Hospital starts program to combat drug withdrawal with long-lasting medication
A pilot program from MultiCare Deaconess Hospital now provides long lasting opioid withdrawal medication. The injectable buprenorphine will provide a much more stable basis for patients to ...
More than 15 years ago, Yale’s Gail D’Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.
Brixadi (buprenorphine) is a prescription injection that’s used to treat opioid use disorder (OUD). It comes as a solution in prefilled syringes and is given weekly or monthly by a healthcare ...
More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.
BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...
About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va.
CORRECTION: Bicycle Health Tackles Nation’s #1 Health Crisis - Opioid Use Disorder - with Prescriptions for Buprenorphine with Pharmacist Injection Services Available at Over 700 Albertsons Companies ...
Local News Matters on MSN
San Francisco sees spike in overdose deaths as health officials pilot injectable treatment
The San Francisco Department of Public Health is trying out new strategies to tackle the city's drug crisis after seeing a ...
The US Food and Drug Administration (FDA) has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results